Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience

[1]  B. Escribano,et al.  SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19 , 2022, Journal of Neurology.

[2]  J. Al-Tawfiq,et al.  Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines , 2022, Infection and drug resistance.

[3]  A. Copas,et al.  Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study , 2022, The Lancet Healthy Longevity.

[4]  M. Inglese,et al.  Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients , 2022, Multiple sclerosis.

[5]  F. Mastroianni,et al.  SARS-CoV-2 antibody response after BNT162b2 mRNA vaccine in healthcare workers: Nine-month of follow-up , 2022, Vaccine: X.

[6]  A. Bertozzi,et al.  Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis , 2022, Journal of Neurology.

[7]  M. Massari,et al.  Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study , 2022, BMJ.

[8]  P. Moss.  The T cell immune response against SARS-CoV-2 , 2022, Nature Immunology.

[9]  O. A. Ogun,et al.  Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study , 2022, The Lancet Regional Health - Americas.

[10]  A. Achiron,et al.  COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose , 2022, Journal of the Neurological Sciences.

[11]  C. Bassetti,et al.  Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System , 2022, Therapeutic advances in neurological disorders.

[12]  V. Di Lazzaro,et al.  Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies , 2021, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.

[13]  A. ten Brinke,et al.  Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate? , 2021, Multiple Sclerosis and Related Disorders.

[14]  V. Tomassini,et al.  mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[15]  T. Fiolet,et al.  Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review , 2021, Clinical Microbiology and Infection.

[16]  M. Ulivelli,et al.  Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies , 2021, EBioMedicine.

[17]  E. Wherry,et al.  Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.

[18]  C. Oreja-Guevara,et al.  Risk and outcomes of COVID‐19 in patients with multiple sclerosis , 2021, European journal of neurology.

[19]  C. Louapre,et al.  Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination? , 2021, Multiple sclerosis.

[20]  A. Achiron,et al.  COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 , 2021, Multiple sclerosis.

[21]  A. Lascano,et al.  Risk of MS relapse after yellow fever vaccination , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[22]  A. Jawad,et al.  Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination , 2013, Journal of Clinical Immunology.

[23]  J. Correale,et al.  Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. , 2011, Archives of neurology.

[24]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[25]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[26]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.